{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:19:54Z","timestamp":1789467594876,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.,","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the advances in current healthcare, bone and joint infections (BJIs) are a major clinical challenge that frequently involve prolonged systemic antibiotic use. Healthcare providers consider tedizolid an attractive candidate for therapy in adults and children with BJI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We tested tedizolid against a US and European collection of Gram-positive BJI isolates (n\u205f=\u205f797) consecutively collected from 2014 to 2017.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Organisms were tested by broth microdilution susceptibility methods following current CLSI guidelines and interpreted by both CLSI and EUCAST breakpoint criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Staphylococcus aureus (59.3%; 58.6% in the USA and 60.4% in Europe) was the most common pathogen with a 29.6% MRSA rate and tedizolid MIC50\/90 of 0.12\/0.25\u2009mg\/L (100% susceptible). CoNS (15.0% of BJI in adults and &lt;5% in children) had tedizolid MIC50\/90 values of 0.12\/0.12\u2009mg\/L (99.1% susceptible). Tedizolid exhibited MIC50\/90 values of 0.12\/0.25\u2009mg\/L for all streptococci and enterococci. Overall, high susceptibility rates (&gt;95%) for vancomycin, daptomycin and linezolid were observed and, based on MIC90 values, tedizolid (MIC90 0.12\u20130.25\u2009mg\/L) was 4- to 8-fold more potent than linezolid (MIC90 0.5\u20132 \u2009mg\/L) against this collection of Gram-positive pathogens causing BJI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study showed that tedizolid had potent in vitro activity against contemporary Gram-positive cocci causing BJI in adults and children in US and European hospitals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz120","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T23:20:40Z","timestamp":1551914440000},"page":"1928-1933","source":"Crossref","is-referenced-by-count":13,"title":["Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014\u201317)"],"prefix":"10.1093","volume":"74","author":[{"given":"Cecilia G","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lio S","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2019072609303104700_dkz120-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019072609303104700_dkz120-B2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.idc.2017.01.010","article-title":"Osteomyelitis","volume":"31","author":"Schmitt","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"2019072609303104700_dkz120-B3","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dku247","article-title":"Epidemiology and burden of prosthetic joint infections","volume":"69","author":"Lamagni","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019072609303104700_dkz120-B4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2019072609303104700_dkz120-B5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/cid\/ciy584","article-title":"A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology","volume":"67","author":"Miller","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019072609303104700_dkz120-B6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"2019072609303104700_dkz120-B7","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019072609303104700_dkz120-B8","year":"2017"},{"key":"2019072609303104700_dkz120-B9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the management of human infections: in vitro characteristics","volume":"58","author":"Locke","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019072609303104700_dkz120-B10","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eleventh Edition: M07","year":"2018"},{"key":"2019072609303104700_dkz120-B11","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Eighth Edition: M100","year":"2018"},{"key":"2019072609303104700_dkz120-B12"},{"key":"2019072609303104700_dkz120-B13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1099\/jmm.0.000595","article-title":"In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections","volume":"66","author":"Ract","year":"2017","journal-title":"J Med Microbiol"},{"key":"2019072609303104700_dkz120-B14","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014","volume":"60","author":"Pfaller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019072609303104700_dkz120-B15","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1128\/AAC.00458-12","article-title":"In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections","volume":"56","author":"Prokocimer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019072609303104700_dkz120-B16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"2019072609303104700_dkz120-B17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019072609303104700_dkz120-B18","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/jac\/dky099","article-title":"ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries","volume":"73","author":"Mendes","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019072609303104700_dkz120-B19","doi-asserted-by":"crossref","first-page":"e00609-17","DOI":"10.1128\/AAC.00609-17","article-title":"Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important Gram-positive cocci in the United States from the LEADER Surveillance Program (2011 to 2015)","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019072609303104700_dkz120-B20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.diagmicrobio.2016.10.009","article-title":"Surveillance of tedizolid activity and resistance: in vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe","volume":"87","author":"Bensaci","year":"2017","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/7\/1928\/29006747\/dkz120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T08:38:52Z","timestamp":1569314332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/7\/1928\/5424101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz120","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,4,1]]}}}